Combined Therapy of Alpha-1-Antitrypsin and Temporal T-Cell Depletion for Preventing Graft Rejection

Eli Lewis (Inventor)

Research output: Patent

Abstract

A method of preventing or treating xenotransplant rejection in a subject in need thereof is disclosed. The method comprises administering a therapeutically effective amount of alpha-1-antitrypsin (AAT) in combination with a therapeutically effective amount of an anti-CD8 antibody or an antigen binding fragment thereof.
Original languageEnglish GB
Patent numberUS10086070B2
StatePublished - 1 Oct 2018

Fingerprint

Dive into the research topics of 'Combined Therapy of Alpha-1-Antitrypsin and Temporal T-Cell Depletion for Preventing Graft Rejection'. Together they form a unique fingerprint.

Cite this